AA
NVO

Auxano Advisors’s Novo Nordisk NVO Stock Holding History

Auxano Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.36M Buy
64,308
+14,404
+29% +$682K 0.47% 35
2025
Q4 		$2.54M Buy
49,904
+3,064
+7% +$157K 0.5% 29
2025
Q3 		$2.6M Buy
46,840
+5,578
+14% +$327K 0.55% 26
2025
Q2 		$2.85M Buy
41,262
+1,870
+5% +$127K 0.67% 23
2025
Q1 		$2.74M Buy
39,392
+8,949
+29% +$739K 0.72% 24
2024
Q4 		$2.62M Buy
30,443
+429
+1% +$46.4K 0.66% 23
2024
Q3 		$3.57M Sell
30,014
-13
-0% -$1.73K 0.93% 19
2024
Q2 		$4.29M Sell
30,027
-208
-0.7% -$27.6K 1.19% 18
2024
Q1 		$3.88M Buy
30,235
+587
+2% +$69.9K 1.13% 18
2023
Q4 		$3.07M Sell
29,648
-180
-0.6% -$17.8K 1.03% 20
2023
Q3 		$2.71M Sell
29,828
-23,442
-44% -$2.07M 1.11% 19
2023
Q2 		$4.24M Hold
53,270
– – 1.7% 14
2023
Q1 		$4.24M Sell
53,270
-2,322
-4% -$165K 1.7% 14
2022
Q4 		$3.76M Buy
55,592
+154
+0.3% +$9.03K 1.7% 14
2022
Q3 		$2.76M Buy
55,438
+3,970
+8% +$213K 1.27% 17
2022
Q2 		$2.87M Buy
51,468
+1,386
+3% +$76.9K 1.42% 17
2022
Q1 		$2.78M Buy
50,082
+272
+0.5% +$14K 1.18% 18
2021
Q4 		$2.79M Buy
49,810
+116
+0.2% +$6.28K 1.25% 19
2021
Q3 		$2.39M Sell
49,694
-904
-2% -$43.7K 1.07% 19
2021
Q2 		$2.12M Buy
50,598
+528
+1% +$20.5K 0.97% 20
2021
Q1 		$1.69M Buy
50,070
+1,428
+3% +$50.9K 1.04% 23
2020
Q4 		$1.7M Buy
48,642
+2,304
+5% +$79.6K 1.12% 19
2020
Q3 		$1.61M Buy
46,338
+2,466
+6% +$82.2K 1.24% 19
2020
Q2 		$1.44M Buy
43,872
+350
+0.8% +$11.2K 1.19% 21
2020
Q1 		$1.31M Buy
+43,522
New +$1.3M 1.19% 21

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Auxano Advisors's NVO Position: Q1 2026 in Review

Auxano Advisors increased its Novo Nordisk (NVO) stake by 29% in Q1 2026, buying an estimated $682K and bringing the position to 64,308 shares worth $2.36M. The position accounts for 0.47% of the portfolio, ranked #35.

Auxano Advisors first reported a position in NVO in Q1 2020 and has held it in 25 quarters since. The position peaked at $4.29M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Auxano Advisors held 64,308 shares of Novo Nordisk worth $2.36M as of Q1 2026.
  • Auxano Advisors bought 14,404 Novo Nordisk shares in Q1 2026, an estimated $682K.
  • Novo Nordisk made up 0.47% of Auxano Advisors's portfolio in Q1 2026, its #35 holding.
  • Auxano Advisors first reported a position in Novo Nordisk in Q1 2020 and has held it in 25 quarters since.
  • Auxano Advisors's Novo Nordisk position peaked at $4.29M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Auxano Advisors's 13F filing for Q1 2026, filed 4 May 2026.